Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
Avadel Pharmaceutics’ $125 Million follow-on Equity Offering
OncoC4’s Strategic Collaboration with BioNTech
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
TPI Composites’ $132.5 Million Convertible Notes Offering
Goodwin Procter advised TPI Composites, Inc. on the deal. Davis Polk advised the representative of the initial purchasers and the counterparties to the capped call transactions...
TCR² Therapeutics’ Agreement with Adaptimmune Therapeutics
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
Bicara Therapeutics’ $108 Million Series B Financing
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
SonoThera’s $60.75 Million Series A Funding
Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
Entrada Therapeutics’ Global Collaboration with Vertex Pharmaceuticals Incorporated
Goodwin Procter advised Entrada Therapeutics, Inc. on the deal. Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus...
FibroGen’s Royalty Monetization Financing with NovaQuest Capital Management
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
Nimbus Therapeutics’ Research Collaboration and License Agreement with Eli Lilly and Co.
Goodwin Procter advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide...
Sarepta Therapeutics’ $1.15 Billion Notes Offering
Goodwin Procter advised the initial purchasers on the deal. Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion...